KCNC4 encodes Kv3.4, a voltage-gated potassium channel that opens in response to transmembrane voltage gradients, permitting potassium ion flow according to their electrochemical gradient 1. The channel displays rapid activation and inactivation kinetics 1 and is expressed in cardiac tissue, with Kv3.4 transcripts highly abundant in both human atrium and ventricle 2. KCNC4 is located on chromosome 1 3. Disease relevance: KCNC4 has emerged as a candidate gene in multiple neurodevelopmental and genetic conditions. It was identified as a novel candidate risk gene for autism spectrum disorder in a Qatari cohort 4 and as a candidate disease gene in a Saudi Arabian diagnostic sequencing study of Mendelian phenotypes 5. In osteosarcoma, KCNC4 functions as a target of miR-214-3p within a regulatory axis involving the long non-coding RNA LINC01535; KCNC4 overexpression promotes osteosarcoma cell proliferation, migration, and invasion 6. In head and neck squamous cell carcinomas, increased KCNC4 expression correlates with higher cancer risk and malignant transformation, with functional studies showing that KCNC4 inhibition suppresses cell proliferation via G2/M cell cycle arrest 7. These findings indicate KCNC4 involvement extends beyond ion homeostasis to include roles in neurodevelopmental and oncological processes.